Cancer Treatment Today

Ponatinib (Iclusig, AP24534) was FDA approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trial  and has activity against the T315I mutation, which confers resistant to other CML drugs. It targets the Bcr-Abl tyrosine kinase, as well as VEGFR, PDGFR, FGFR, the SRC kinases,

Personalized Medicine is the cutting edge of diagnostic science and cancer treatment. Advancement of science enables doctors to obtain a variety of markers in cancer tissues from a biopsy or after surgery of a particular cancer. Some of these markers are purely prognostic but some are targets for drugs that are already approved, or are being researched, although they may not be approved for this particular cancer. In other words, these drugs are